牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-039788 Act: 34 Size: 133 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-038922 Act: 34 Size: 21 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-037109 Act: 34 Size: 27 KB 网页链接
$灿菲特生物制药(CANF)$ F-6EF Registration of American Depository Receipt shares, immediately effective Accession Number: 0001019155-20-000394 Act: 33 Size: 261 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-033709 Act: 34 Size: 622 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-030968 Act: 34 Size: 25 KB 网页链接
$灿菲特生物制药(CANF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-20-002807 Act: 33 Size: 1 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-030201 Act: 34 Size: 37 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-029084 Act: 34 Size: 32 KB 网页链接
$灿菲特生物制药(CANF)$ F-3 Registration statement by foreign private issuers Accession Number: 0001213900-20-028478 Act: 33 Size: 605 KB 网页链接